Theriva Biologics
TOVX
Theriva Biologics (TOVX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.93
- EPS estimate
- −$0.78
- EPS surprise
- −149.03%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 11, 2025 | −$0.78 | −$1.93 | −149.03% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$4.19 | −$1.55 | +63.01% | $0.00 | SEC |
| Q4 2024 | Mar 6, 2025 | −$7.22 | $6.03 | +183.52% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$6.25 | −$6.81 | −8.96% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$4.75 | −$10.75 | −126.32% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$4.75 | −$7.50 | −57.89% | $0.00 | SEC |
| Q4 2023 | Mar 25, 2024 | −$10.25 | −$7.75 | +24.39% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$10.50 | −$4.75 | +54.76% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$9.00 | −$8.50 | +5.56% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$8.88 | −$7.50 | +15.49% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$8.38 | −$9.25 | −10.45% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$9.25 | −$8.25 | +10.81% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$8.75 | −$7.75 | +11.43% | $0.00 | — |
| Q1 2022 | May 16, 2022 | −$7.50 | −$7.50 | +0.00% | $0.00 | — |
| Q4 2021 | Mar 16, 2022 | −$6.25 | −$5.00 | +20.00% | $0.00 | — |
| Q3 2021 | Nov 3, 2021 | −$7.50 | −$5.00 | +33.33% | $0.00 | — |
| Q2 2021 | Aug 5, 2021 | −$5.00 | −$5.00 | +0.00% | $0.00 | — |
| Q1 2021 | May 5, 2021 | −$5.00 | −$32.50 | −550.00% | $0.00 | — |
| Q4 2020 | Mar 4, 2021 | −$20.00 | −$35.00 | −75.00% | $0.00 | SEC |
| Q3 2020 | Nov 10, 2020 | −$42.50 | −$35.00 | +17.65% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Theriva Biologics (TOVX) last report earnings?
Theriva Biologics last reported on Aug 11, 2025, covering fiscal Q2 2025.
Did TOVX beat earnings estimates?
No. Theriva Biologics reported EPS of −$1.93 for Q2 2025 against a −$0.78 estimate — a 149.03% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.